Results 111 to 120 of about 1,680 (126)
Some of the next articles are maybe not open access.
Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement
Pathology, 2022Emicizumab is a recombinant, humanised bispecific antibody which acts as a FVIII mimetic and is a therapeutic option for haemophilia A. Plasma emicizumab levels may sometimes be required. Multiple one-stage clotting assays (OSA) and one human component chromogenic assay (CSA) were used to measure emicizumab both centrally and by a field study.
Geoffrey Kershaw +4 more
openaire +2 more sources
Emicizumab-kxwh: First Global Approval
Drugs, 2018Emicizumab-kxwh (Hemlibra®) is a bispecific humanized monoclonal antibody that restores the function of missing activated FVIII by bridging activated FIX and FX to facilitate effective haemostasis in patients with haemophilia A. Subcutaneous emicizumab-kxwh is approved in the USA for use as routine prophylaxis to prevent or reduce the frequency of ...
Lesley J, Scott, Esther S, Kim
openaire +2 more sources
Emicizumab treatment in chronic intermittent haemodialysis
Haemophilia, 2021Maria Weise +6 more
openaire +2 more sources